Clinical Trial Update: Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating quizartinib with azacitidine or cytarabine in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CYTARABINE (CYTARABINE)
• Quizartinib (Quizartinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-02-28